Guang-Yu Liu
Overview
Explore the profile of Guang-Yu Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen L, Wu W, Liang F, Liu G, Yu K, Wu J, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39754712
Background: Hormone receptor-positive (HR+)/humaal growth factor receptor 2-negative (HER2-) breast cancer, the most common breast cancer type, has variable prognosis and high recurrence risk. Neoadjuvant therapy is recommended for median-high...
2.
Wu H, Gong Y, Ling Y, Wu S, Ji P, Zhao Q, et al.
Med
. 2024 Nov;
6(3):100535.
PMID: 39520982
Background: Although the prognosis of triple-negative breast cancer (TNBC) has significantly improved in the era of immunotherapy, many TNBC patients are resistant to therapies, and their disease progresses rapidly. Deciphering...
3.
He M, Jiang Y, Gong Y, Fan L, Liu X, Liu Y, et al.
BMJ
. 2024 Oct;
387:e079603.
PMID: 39442958
Objective: To evaluate the feasibility of using a multigene signature to tailor individualised adjuvant therapy for patients with operable triple negative breast cancer. Design: Randomised, multicentre, open label, phase 3...
4.
Zuo W, Chen L, Shen Y, Wang Z, Liu G, Yu K, et al.
Ther Adv Med Oncol
. 2024 Feb;
16:17588359231225032.
PMID: 38362377
Background: With our growing insight into the molecular heterogeneity and biological characteristics of breast cancer, individualized treatment is the future of cancer treatment. In this prospective Fudan University Shanghai Cancer...
5.
Chen S, Zhang F, Zhang Y, Liao L, Deng L, Shao Z, et al.
Cancer Lett
. 2024 Jan;
586:216672.
PMID: 38280476
Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer with no targeted therapy. Spermatid perinuclear RNA binding protein (STRBP), a poorly characterized RNA-binding protein (RBP), has an...
6.
Liu G, Yu D, Fan M, Zhang X, Jin Z, Tang C, et al.
Mil Med Res
. 2024 Jan;
11(1):7.
PMID: 38254241
Antimicrobial resistance is a global public health threat, and the World Health Organization (WHO) has announced a priority list of the most threatening pathogens against which novel antibiotics need to...
7.
Fan L, Wang Z, Ma L, Wu S, Wu J, Yu K, et al.
Lancet Oncol
. 2024 Jan;
25(2):184-197.
PMID: 38211606
Background: Triple-negative breast cancers display heterogeneity in molecular drivers and immune traits. We previously classified triple-negative breast cancers into four subtypes: luminal androgen receptor (LAR), immunomodulatory, basal-like immune-suppressed (BLIS), and...
8.
Zheng X, Zhang Y, Song W, Liu G, Ding Z, Liu J
Zhongguo Zhong Yao Za Zhi
. 2023 Dec;
48(21):5863-5870.
PMID: 38114182
This study aims to investigate the effects of baicalein(BAI) on lipopolysaccharide(LPS)-induced human microglial clone 3(HMC3) cells, with a focus on suppressing inflammatory responses and elucidating the potential mechanism underlying the...
9.
Zhao Q, Yang F, Wu H, Mo M, Ling Y, Liu G
Breast
. 2023 Oct;
72:103589.
PMID: 37839139
Background: Contralateral axillary lymph node metastasis (CAM) is rare. It remains controversial whether CAM should be regarded as a regional or distant metastatic disease. Our study aims to investigate the...
10.
Ling Y, Xie Y, Wu H, Wang X, Ma J, Fan L, et al.
Breast
. 2023 Jun;
70:63-69.
PMID: 37352573
Background: Disease progression during neoadjuvant systemic therapy for breast cancer indicates poor prognosis, while predictors of the clinical outcomes of these patients remain unclear. By comparing the clinical outcomes of...